Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients

Larenas‐Linnemann, Désirée; Morfín-Maciel, Blanca María; Bedolla-Barajas, Martín; López-Bago, Ana; Rodríguez, Elsy Maureen Navarrete; Martinez, María Dolores Mogica; Gereda, José E.; Sanjuan, Mauricio Sarrazola; Pedroza, Rosa Yazmín Cano; Cavallo, María Cecilia; Tapia, Sergio de Jesús Romero; Jossen, Roberto A.; Pérez, José Miguel Fuentes; Del-Río-Navarro, Blanca E.; Zagal, Erendira Rodríguez; Sosa, Pedro A. Piraino; Huerta-Villalobos, Yunuen Rocío; Chavez-Vereau, Pierre; Imperial, Daniel Alberto García; Gómez, Margarita Olivares; Rodríguez, Francisco Valle; Reyes, Carlos Omar Zuñiga; Rodríguez-González, Mónica; Corella, Claudia Ivonne Gallego; Ivancevich, Juan Carlos; Cruz, María de la Luz Hortencia García; Repka-Ramirez, María Susana; Morales, Mauricio Ernesto Flores; Aguirre, Juan Carlos Fernández De Córdova; Luna-Pech, Jorge A.; Yeverino, Daniela Rivero; Guzmán, Edgar Martínez; Ortiz, Cinthia Elizabeth Pérez; Médica, Leonor Villa

doi:10.1016/j.waojou.2023.100779

Cited by 2 publications

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study

Li,

Chen,

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Background COVID-19 is a new infectious disease. To investigate whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection increases the adverse reactions of subcutaneous specific immunotherapy (SCIT) in children. Methods This study was conducted by collecting relevant data from children who underwent house dust mite SCIT from April 3, 2021, to March 18, 2023, including information on the time of COVID-19 infection, symptoms, and adverse reactions after each allergen injection. A mixed effects model was used to analyze the changes in adverse reactions before and after the COVID-19 infection. Results Among the records of adverse reactions from 2658 injections in 123 children who underwent SCIT, the overall adverse reaction rate before COVID-19 infection was 39.8% and 30.0% after COVID-19 infection. Compared with pre-infection with COVID-19, the risks of overall adverse reactions, local adverse reactions, and systemic adverse reactions of immunotherapy after COVID-19 infection were reduced (odds ratio [OR] = 0.24, 0.31, and 0.28, all P < 0.05). Among the local adverse reactions, the incidence of the unvaccinated group was the highest (15.3% vs. 7.1%). The incidence of overall and local adverse reactions to SCIT decreased in 2-vaccinated COVID-19 recipients (OR = 0.29–0.31, P < 0.05). Conclusions In children, SARS-CoV-2 infection does not increase the incidence of adverse reactions to SCIT. This finding can provide a basis for the implementation of allergen-specific immunotherapy (AIT) during the COVID-19 pandemic. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-024-09702-5.

show abstract

Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study

Li,

Chen,

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

Desensitization reduces some COVID-19-associated symptoms in minors with allergic rhinitis

Zhang,

Liu,

Zhang

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective The aim of this study was to observe the symptoms after infection with coronavirus disease 19 (COVID-19) in minor and adult allergic rhinitis (AR) patients receiving different treatment therapies [Sublingual immunotherapy (SLIT) and conventional therapy]. Methods We recruited a total of 398 patients diagnosed with AR from the clinical system and divided them into AR-S, with AR-S1 representing individuals aged < 18 years of age, and AR-S2 those ≥ 18 years of age, and AR-C groups based on their treatment modalities. Between December 2022 and February 2023, we documented the respiratory symptoms and common manifestations of AR patients infected with the novel coronavirus. Results The AR-S1 group may be associated with a reduced risk of symptoms after infection including dry and itchy (OR = 0.373, 95%Cl:0.184–0.755), headache (OR = 0.385, 95%Cl:0.196–0.758), fatigue (OR = 0.376, 95%Cl:0.188–0.751), chest tightness (OR = 0.160, 95%Cl:0.049–0.522), and some symptoms after improvement of infection (cough, fatigue). Conclusion Minor AR patients with SLIT can reduce some of the symptoms in COVID-19-infected patients. Level of Evidence: 3

show abstract

Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients

Cited by 2 publications

References 31 publications

Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study

Impact of COVID-19 on adverse reactions to subcutaneous specific immunotherapy in children:a retrospective cohort study

Desensitization reduces some COVID-19-associated symptoms in minors with allergic rhinitis

Contact Info

Product

Resources

About